Press Release — Receives IND clearance for Phase 2b program in U.S.–— Topline data from ongoing Phase 2b clinical trial to be reported in Q4 2022 — TEL AVIV, Israel & MELBOURNE, Australia, September 28, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for […]
Press Release — SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement of Azura’s first-in-class Ophthalmic Keratolytics — TEL AVIV, Israel & MELBOURNE, Australia, September 21, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB) Read More »
Press Release — Funding awarded by Brandon BioCatalyst’s CUREator — TEL AVIV, Israel & MELBOURNE, Australia, September 7, 2022 – Azura Ophthalmics Ltd. (Azura), a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the company was awarded a grant from CUREator, Australia’s national biomedical incubator managed by
